Detection and Diagnosis of Pancreatic Cancer
胰腺癌的检测和诊断
基本信息
- 批准号:7271927
- 负责人:
- 金额:$ 23.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-09-09 至 2009-06-30
- 项目状态:已结题
- 来源:
- 关键词:AffinityAntibodiesAntigensAttentionBenignBinding SitesBiologicalBiological AssayBiological MarkersBreastCarbohydratesCessation of lifeCharacteristicsColonColorectalColorectal CancerDetectionDiagnosisDiagnostic ProcedureDiscriminationDiseaseDisease ManagementEarly DiagnosisEnzyme ImmunoassayEpitopesEvaluationGenus ColaGlycoside HydrolasesHeterogeneityImmunoassayIn VitroLiquid substanceLocationLungMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of pancreasMindMolecularMolecular ProfilingMonoclonal AntibodiesMucin-1 Staining MethodMucin-2 Staining MethodMucinsMultivariate AnalysisNatureOligosaccharidesOrganOvaryPancreasPancreatic DiseasesPancreatitisPatientsPatternPeptidesPopulationPost-Translational Protein ProcessingProcessProgress Review GroupProstateRecommendationReportingReproducibilityScreening procedureSensitivity and SpecificitySpecificitySpecimenStagingStandards of Weights and MeasuresStructureStudy SectionSurvival RateTechnologyTimeTissuesTranslatingWomanantigen bindingbasecancer typecarbohydrate structuredesigndiagnostic accuracyglycosyltransferaseimmunoreactivityimprovedmalignant breast neoplasmmenmucin core proteinovarian neoplasmpancreatic neoplasmpeptide structurepolyclonal antibodyprotein aminoacid sequencetumortumor growth
项目摘要
DESCRIPTION (provided by applicant): Pancreatic cancer is one of the most insidious forms of cancer. Recent estimates of new cancer cases put pancreatic cancer at eighth and ninth among women and men, respectively. However, it is the fourth leading cause of all cancer deaths in both women and men, surpassed only by lung, colorectal, prostate, and breast cancers. Due largely to the location, and silent growth of the tumor, most patients present at a time when it is too late to undergo any realistic type of curative treatment. This has translated into a 5-year survival rate of less than 3%. In a recent report, "Pancreatic Cancer: An Agenda for Action", the NCI's Pancreatic cancer Progress Review Group drew specific attention to the urgent need for "better screening and diagnostic techniques" with a recommendation to "delineate and validate effective molecular biomarkers" for pancreatic cancer. With this in mind, we intend to develop and assess the utility of a PAM4, anti-MUC1 antibody-based immunoassay to detect, diagnose, and provide for the management of this disease. Although there have been several reports concerning anti-MUC1 MAbs reactive with several types of cancer, PAM4 appears to be unique, or nearly so, in terms of its specificity and the molecular characteristics of the epitope to which it is reactive. The long-term objective of this proposal is to identify specific biomarkers that can be combined with the PAM4 assay for enhanced diagnostic accuracy of pancreatic cancer. The specific aims of this proposal are Aim 1. To investigate the diagnostic accuracy of an immunoassay for the quantitation of PAM4-reactive MUC1 in biological fluids as a means for early detection and diagnosis of pancreatic cancer. Aim 2. To investigate the heterogeneity in expression of MUC1 epitope structures as a means to identify patterns that may be organ and/or tumor "specific/associated". Aim 3. To investigate whether inclusion of other mucin biomarkers can increase diagnostic accuracy through multivariate analyses.
描述(由申请人提供):胰腺癌是最隐蔽的癌症形式之一。最近对新癌症病例的估计将胰腺癌在女性和男性中分别排在第八位和第九位。然而,它是女性和男性所有癌症死亡的第四大原因,仅次于肺癌,结肠直肠癌,前列腺癌和乳腺癌。主要由于肿瘤的位置和无声生长,大多数患者出现在接受任何现实类型的治愈性治疗时已经太晚了。这意味着5年生存率不到3%。在最近的一份报告中,“胰腺癌:行动议程”,NCI的胰腺癌进展审查小组提请特别注意迫切需要“更好的筛查和诊断技术”,并建议“描绘和验证有效的分子生物标志物”胰腺癌。考虑到这一点,我们打算开发和评估PAM 4,抗MUC 1抗体为基础的免疫测定检测,诊断,并提供这种疾病的管理的效用。尽管已经有几个关于与几种类型的癌症反应的抗MUC 1单克隆抗体的报道,但PAM 4在其特异性和与其反应的表位的分子特征方面似乎是独特的,或几乎如此。该提案的长期目标是确定可以与PAM 4检测相结合的特定生物标志物,以提高胰腺癌的诊断准确性。本提案的具体目标是目标1。研究生物体液中PAM 4反应性MUC 1定量免疫测定的诊断准确性,作为胰腺癌早期检测和诊断的一种手段。 目标二。研究MUC 1表位结构表达的异质性,以鉴定可能是器官和/或肿瘤“特异性/相关”的模式。目标3.通过多变量分析,研究纳入其他粘蛋白生物标志物是否可以提高诊断准确性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID V GOLD其他文献
DAVID V GOLD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID V GOLD', 18)}}的其他基金
相似海外基金
Rationally guided discovery platform for monoclonal antibodies against carbohydrate antigens using virus-like particle conjugate immunization and high throughput selection
使用病毒样颗粒缀合物免疫和高通量选择的合理引导的针对碳水化合物抗原的单克隆抗体的发现平台
- 批准号:
10574738 - 财政年份:2023
- 资助金额:
$ 23.43万 - 项目类别:
Assessing the role of liver stage antigens-specific antibodies against Plasmodium falciparum liver stage infection
评估肝期抗原特异性抗体对抗恶性疟原虫肝期感染的作用
- 批准号:
10392870 - 财政年份:2021
- 资助金额:
$ 23.43万 - 项目类别:
Generation of antibodies specific for optimal non-HRP2 malaria diagnostic antigens
生成最佳非 HRP2 疟疾诊断抗原的特异性抗体
- 批准号:
10092930 - 财政年份:2020
- 资助金额:
$ 23.43万 - 项目类别:
Generation of antibodies specific for optimal non-HRP2 malaria diagnostic antigens
生成最佳非 HRP2 疟疾诊断抗原的特异性抗体
- 批准号:
9896170 - 财政年份:2020
- 资助金额:
$ 23.43万 - 项目类别:
Interrogation of cell surface antigens on B lineage cells using structurally unique variable lymphocyte receptor antibodies of the evolutionarily distant sea lamprey
使用进化遥远的海七鳃鳗结构独特的可变淋巴细胞受体抗体询问 B 谱系细胞上的细胞表面抗原
- 批准号:
433456 - 财政年份:2020
- 资助金额:
$ 23.43万 - 项目类别:
Operating Grants
Investigations of interactions between various natural antibodies and food-derived antigens
研究各种天然抗体与食物源性抗原之间的相互作用
- 批准号:
19K15765 - 财政年份:2019
- 资助金额:
$ 23.43万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Identifying Kawasaki Disease-Specific Antibodies and Antigens
识别川崎病特异性抗体和抗原
- 批准号:
9932769 - 财政年份:2018
- 资助金额:
$ 23.43万 - 项目类别:
Novel Scoring Methods for Interactions between Antibodies and Antigens
抗体和抗原之间相互作用的新评分方法
- 批准号:
BB/P504713/1 - 财政年份:2017
- 资助金额:
$ 23.43万 - 项目类别:
Training Grant
Novel Scoring Methods for Interactions between Antibodies and Antigens
抗体和抗原之间相互作用的新评分方法
- 批准号:
1932904 - 财政年份:2017
- 资助金额:
$ 23.43万 - 项目类别:
Studentship
SBIR Phase II: Automated Design Methods of Antibodies Directed to Protein and Carbohydrate Antigens
SBIR II 期:针对蛋白质和碳水化合物抗原的抗体的自动化设计方法
- 批准号:
1632399 - 财政年份:2016
- 资助金额:
$ 23.43万 - 项目类别:
Standard Grant